Market Place
Sourcing Support
AffaMed Therapeutics Announces NDA Acceptance by HSA for DEXTENZA
19 Feb 2024 //
PR NEWSWIRE
AffaMed Therapeutics Announces First Patient Treated in Ph 3 Trial for DEXTENZA
20 Sep 2023 //
PR NEWSWIRE
Vistagen Reports Positive Results from Phase 3 Trial of Fasedienol Nasal Spray
10 Aug 2023 //
PR NEWSWIRE
AffaMed Announces Completion of Enrollment in Study Evaluating Efficacy of DEXTENZA
31 May 2023 //
PR NEWSWIRE
Prof. Roger D. Kornberg will be joining Tissue Dynamics` advisory board
31 May 2023 //
PR NEWSWIRE
AffaMed Therapeutics Announces Partner Allgenesis Reports Data from the AG-73305
25 May 2023 //
PR NEWSWIRE
AffaMed Therapeutics Announces Approval to Initiate a Ph3 TriaL
17 Apr 2023 //
PR NEWSWIRE
AffaMed completes first patient implantation in the China Registrational Trial
06 Mar 2023 //
PHARMABIZ
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention
17 Jan 2023 //
PR NEWSWIRE
AffaMed Begins Dosing in the US PI Trial of AM712 in Retinal Disease
30 May 2022 //
PRNEWSWIRE
AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
10 May 2022 //
ASIAONE
VistaGen and AffaMed complete regulatory submissions for Phase III SAD trial
13 Apr 2022 //
PHARMAFILE
AffaMed Announces New Drug Approval for DEXTENZA in Ocular Inflammation and Pain
12 Apr 2022 //
PRNEWSWIRE
US FDA gives clearance to AffaMed’s bispecific biologic in AMD
16 Feb 2022 //
EXPRESSPHARMA
FDA Clears AffaMed`s IND for AM712 in Retinal Vascular Diseases
15 Feb 2022 //
PRNEWSWIRE
AffaMed begins patient dosing in clinical trial of Dextenza
21 Jan 2022 //
PHARMABIZ
AffaMed Doses First Patient in Trial Evaluating DEXTENZA in Cataract Surgery
18 Jan 2022 //
BUSINESSWIRE
AffaMed Therapeutics establishes AffaMed Digital to advance digital medicines
11 Nov 2021 //
PHARMABIZ
AffaMed Therapeutics Enters into Strategic Partnership Agreement
07 Sep 2021 //
BIOSPACE
AffaMed signs deal with Beijing Tiantan Hospital & IBT for Digital Therapy
05 Sep 2021 //
PRNEWSWIRE
AffaMed Announces Approval for the Phase IIb Clinical Study of AM006 in China
27 May 2021 //
PRNEWSWIRE
AffaMed Announces Approval for the Phase IIb Clinical Study of AM006
27 May 2021 //
PRNASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.